Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer.

نویسندگان

  • Alexandros S Ardavanis
  • Georgios N Ioannidis
  • George S Orphanos
  • Gerassimos A Rigatos
چکیده

BACKGROUND Refractory and/or relapsing advanced colorectal cancer (ACRC) requires frequent and prolonged hospitalisations, with a negative impact on the patients' quality of life (QoL). The aim of this single-centre, phase II study was to investigate the efficacy and safety of capecitabine (C) as salvage therapy in patients (pts) with ACRC, heavily pretreated with various chemotherapeutic regimens, as well as radiotherapy. PATIENTS AND METHODS A total of 28 pts were enrolled, with the following characteristics: 16 male and 12 female, median age 60 years (36-70) and median ECOG PS 1 (0-2). All pts had previously received at least 2 regimens of standard chemotherapy, including 5-FU/leucovorin, oxaliplatin and irinotecan in various combinations, while 8 pts had been offered radiotherapy. Four pts had already been treated with C. The treatment was administered at home and consisted of C at a dose of 1250 mg/m2 twice daily on days 1-14, every 3 weeks, until disease progression (PD) and for a maximum of 9 cycles. Since grade (G) 3 gastrointestinal (GI) toxicity was observed among the first 7 pts, a daily dose of 2 g/m2 was adopted in the subsequent enrolment. RESULTS The disease control (DC) rate was 53% (95% CI: 33.8%-72.5%): partial response in 2 pts and disease stabilization in 13 pts. Three out of 4 pts previously exposed to C showed stable disease. A significant symptom improvement was demonstrated in all 4pts with non-measurable baseline disease. The median time to progression was 4 months (range: 2-7). Nine pts had PD while on treatment. The median overall survival times for pts with DC and PD were 6 months and 3 months, respectively. Various types of G3 haematological toxicity were observed in 4/28 pts, G3 hand-foot syndrome in 6/28 pts and G3 GI toxicity in 8/28 pts. Nevertheless, the patients' QoL and the regimen's safety profile were satisfactorily preserved. CONCLUSION Despite its methodological limitations, our trial suggests that salvage treatment of heavily pretreated ACRC with single-agent C may be considered a safe and cost-effective alternative to best supportive care.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Metronomic Capecitabine for Elderly Advanced Gastric Carcinoma Patients Pretreated With One or Two Systemic Chemotherapy Lines

Background: The aim of this study was to investigate the efficacy and safety of metronomic capecitabine chemotherapy in pretreated elderly patients with advanced gastric carsonoma. Patients and Methods: Eligible patients were treated with capecitabine at a fixed dose of 1000mg daily until disease progression or toxicity. Endpoints were overall response rate, safety, progression-free survival...

متن کامل

The role of capecitabine in first-line treatment for patients with metastatic breast cancer.

Capecitabine is an important drug in the therapeutic armamentarium for metastatic breast cancer. A comprehensive worldwide clinical trial program involving >10,000 patients with locally advanced and metastatic breast cancer has provided evidence for the current treatment strategies. On the basis of data demonstrating consistent activity across several trials in patients with heavily pretreated ...

متن کامل

Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.

BACKGROUND Capecitabine (Xeloda) is a fluoropyrimidine which is transformed to 5-fluorouracil (5-FU) at the tumor site. The aim of the present study was to estimate the efficacy of this agent in pretreated patients with advanced breast and colorectal cancer, and to determine the response rate and adverse reactions. PATIENTS AND METHODS Forty-two patients (median age 65 years, range 27-80 year...

متن کامل

Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.

PURPOSE To model the cost-effectiveness of adopting capecitabine/docetaxel combination therapy in place of single-agent taxane therapy for women in the province of Ontario, Canada, receiving treatment for anthracycline-pretreated metastatic breast cancer. METHODS Clinical effectiveness and economic data were combined in a population model, from the perspective of a universal health care syste...

متن کامل

Ixabepilone development across the breast cancer continuum: a paradigm shift

The epothilone analog ixabepilone exhibits reduced susceptibility to several important tumor survival mechanisms that limit the efficacy of taxanes and anthracyclines. As a single agent, ixabepilone has shown promise in metastatic breast cancer when anthracyclines, taxanes, or capecitabine have failed; and in early-stage breast cancer that is taxane-naïve or has previously received taxanes in t...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Anticancer research

دوره 26 2B  شماره 

صفحات  -

تاریخ انتشار 2006